Zobrazeno 1 - 3
of 3
pro vyhledávání: '"S. D. Van Haren"'
Autor:
Ruth A. Ettinger, Jan Voorberg, S. D. Van Haren, Kathleen P. Pratt, Eddie A. James, Karin Fijnvandraat, William W. Kwok, Joseph A. Liberman
Publikováno v:
Journal of thrombosis and haemostasis, 9(4), 689-699. Wiley-Blackwell
Summary. Background: Development of neutralizing anti-factor (F)VIII antibodies (‘inhibitors’) is a serious clinical problem in hemophilia A. Increased inhibitor risk has been associated with certain FVIII missense substitutions, including R593C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bcaae37478bc34e36093c2afe02bbea
https://doi.org/10.1111/j.1538-7836.2011.04202.x
https://doi.org/10.1111/j.1538-7836.2011.04202.x
Autor:
S. D. Van Haren, Jan Voorberg, P. M. W. Van Helden, H. Marijke van den Berg, Karin Fijnvandraat
Publikováno v:
Haemophilia. 16:35-43
Summary. Development of inhibitory antibodies to factor VIII (FVIII) provides a major complication of replacement therapy in patients with haemophilia A. The risk of inhibitor formation is influenced by the underlying FVIII gene defect. Moreover, gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e6bcf21a61dbb99b35e04d85b1a5cd2
https://doi.org/10.1111/j.1365-2516.2010.02215.x
https://doi.org/10.1111/j.1365-2516.2010.02215.x
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 16(102)
Development of inhibitory antibodies to factor VIII (FVIII) provides a major complication of replacement therapy in patients with haemophilia A. The risk of inhibitor formation is influenced by the underlying FVIII gene defect. Moreover, genetic dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd533f068e392820d75c2b2bf191846a
https://pubmed.ncbi.nlm.nih.gov/20536984
https://pubmed.ncbi.nlm.nih.gov/20536984